產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白與其它公司提供的重組蛋白不同，rHuMCP-1/CCL2蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白
| Synonyms | HC11, Monocyte chemoattractant protein 1, MCAF, MCP-1, Monocyte secretory protein JE, Small-inducible cytokine A2 |
| Species | Human |
| Accession | P13500 |
| GeneID | 6347 |
| Source | 重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白Escherichia coli. |
| Molecular Weight | Approximately 8.7 kDa, a single non-glycosylated polypeptide chain containing 76 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | QPDAINAPVT CCYNFTNRKI SVQRLASYRR ITSSKCPKEA VIFKTIVAKE ICADPKQKWV QDSMDHLDKQ TQTPKT |
| Purity | > 96 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration range of 10-100 ng/ml. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 100 mM NaCl. |
| Endotoxin | Less than 1 EU/μg of rHuMCP-1/CCL2 as determined by LAL method. |
| Reconstitution | 重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人類單核細(xì)胞趨化蛋白-1 / CCL2蛋白 | |
| Reference |
1. Carr MW, Roth SJ, Luther E, et al. 1994. Proc Natl Acad Sci U S A. 91:3652-6. 2. Yoshimura T, Yuhki N, Moore SK, et al. 1989. FEBS Lett. 244:487-93. 3. Furutani Y, Nomura H, Notake M, et al. 1989. Biochem Biophys Res Commun. 159:249-55. 4. Craig MJ, Loberg RD. 2006. Cancer Metastasis Rev. 25:611-9. 5. Conti P, Boucher W, Letourneau R, et al. 1995. Immunology. 86:434-40. 6. Bischoff SC, Krieger M, Brunner T, et al. 1992. J Exp Med. 175:1271-5. 7. Xia M, Sui Z. 2009. Expert Opin Ther Pat. 19:295-303. 8. Lloyd CM, Minto AW, Dorf ME, et al. 1997. J Exp Med. 185:1371-80. |
| Background | CCL2, also named monocyte chemotactic protein-1 (MCP-1) and small inducible cytokine A2, is a small cytokine that belongs to the CC chemokine family. It is a monomeric polypeptide, with a molecular weight of approximately 13 kDa and it is anchored in the plasma membrane of endothelial cells by glycosaminoglycan side chains of proteoglycans. Research shows that CCR2 and CCR4 are two cell surface receptors that bind CCL2. CCL2 exhibits a chemotactic activity for monocytes and basophils. However, it does not attract neutrophils or eosinophils. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis and it may be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. Mature human CCL2 shares 78-79 % a.a. identity with canine, porcine and equine CCL2, while mouse and rat express a form of CCL2 that is extended by 49 a.a. and shares only ~56 % a.a. identity within the common region. |
